This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
AC Immune, Ltd.
Drug Names(s): PSY 130/131
Description: ACI-91 is an orally administered, muscarinic acetylcholine inhibitor which indirectly down-regulates the expression and activity of the beta-secretase BACE-1 in pre-clinical studies.
Deal Structure: ACI-91 was in-licensed by AC Immune from an unnamed company, presumably Prosteosys AG. According to Prosteosys, PSY-130/131 was a reprofiled molecule for Alzheimer's disease that was outlicensed to AC Immune.
Partners: ProteoSys AG
Additional information available to subscribers only: